自体99mTc标记中性粒细胞定量COPD肺内中性粒细胞清除
研究采用自体99mTc标记中性粒细胞与SPECT/CT,量化健康志愿者吸入LPS或盐水后及COPD患者全肺中性粒细胞累积。COPD患者和LPS刺激者肺内标记中性粒细胞累积显著高于盐水对照,且COPD患者7-10天后重复成像重现性高,提示该方法可用于评估靶向中性粒细胞迁移药物的疗效。
要点
- COPD患者全肺中性粒细胞累积显著高于盐水对照。
- 吸入LPS健康志愿者中性粒细胞累积亦显著增高。
- COPD患者重复成像7-10天重现性高,支持疗效评估。
核心结论
- 自体99mTc标记中性粒细胞联合SPECT/CT可定量健康志愿者吸入LPS后及COPD患者全肺中性粒细胞累积。
- 该方法重现性高,支持用于评估改变中性粒细胞肺迁移药物的疗效。
研究设计与样本
- 研究纳入20例COPD患者(GOLD 2-3期)和18例健康志愿者。
- 健康志愿者吸入盐水(n=6)或LPS(50 µg,n=12)后注射放射性标记细胞。
- 中性粒细胞经右旋糖酐沉降和Percoll血浆梯度分离,用99mTc-HMPAO标记。
- SPECT于45分钟、2小时、4小时和6小时采集,Patlak-Rutland图分析肺血中性粒细胞清除。
主要发现
- 盐水对照组肺中性粒细胞累积为0.0006±0.0003 mL/min/mL(均值±1 SD)。
- COPD患者累积为0.0022±0.0010 mL/min/mL,较盐水组显著增高(p<0.001)。
- LPS刺激组累积为0.0025±0.0008 mL/min/mL,较盐水组显著增高(p<0.001)。
- 10例COPD患者7-10天后重复标记成像,累积为0.0022±0.0010 vs 0.0023±0.0009 mL/min/mL,重现性高。
- COPD患者基线IL-6为1.5±1.06 pg/mL,高于健康志愿者的0.4±0.24 pg/mL;LPS刺激后9小时IL-6升至7.5±2.72 pg/mL。
临床怎么用
- 该成像方法可用于量化COPD患者全肺中性粒细胞累积。
- 高重现性支持将其作为评估靶向中性粒细胞迁移治疗药物的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: There is a need to develop imaging protocols which assess neutrophilic inflammation in the lung. AIM: To quantify whole lung neutrophil accumulation in (1) healthy volunteers (HV) following inhaled lipopolysaccharide (LPS) or saline and (2) patients with COPD using radiolabelled autologous neutrophils and single-photon emission computed tomography/CT (SPECT/CT). METHODS: 20 patients with COPD (Global initiative for chronic obstructive lung disease (GOLD) stages 2-3) and 18 HVs were studied. HVs received inhaled saline (n=6) or LPS (50 µg, n=12) prior to the injection of radiolabelled cells. Neutrophils were isolated using dextran sedimentation and Percoll plasma gradients and labelled with 99mTechnetium (Tc)-hexamethylpropyleneamine oxime. SPECT was performed over the thorax/upper abdomen at 45 min, 2 hours, 4 hours and 6 hours. Circulating biomarkers were measured prechallenge and post challenge. Blood neutrophil clearance in the lung was determined using Patlak-Rutland graphical analysis. RESULTS: There was increased accumulation of 99mTc-neutrophils in the lungs of patients with COPD and LPS-challenged subjects compared with saline-challenged subjects (saline: 0.0006±0.0003 mL/min/mL lung blood distribution volume [mean ±1 SD]; COPD: 0.0022±0.0010 mL/min/mL [p<0.001]; LPS: 0.0025±0.0008 mL/min/mL [p<0.001]). The accumulation of labelled neutrophils in 10 patients with COPD who underwent repeat radiolabelling/imaging 7-10 days later was highly reproducible (0.0022±0.0010 mL/min/mL vs 0.0023±0.0009 mL/min/mL). Baseline interleukin (IL)-6 levels in patients with COPD were elevated compared with HVs (1.5±1.06 pg/mL [mean ±1 SD] vs 0.4±0.24 pg/mL). LPS challenge increased the circulating IL-6 levels (7.5±2.72 pg/mL) 9 hours post challenge. CONCLUSIONS: This study shows the ability to quantify 'whole lung' neutrophil accumulation in HVs following LPS inhalation and in subjects with COPD using autologous radiolabelled neutrophils and SPECT/CT imaging. Moreover, the reproducibility observed supports the feasibility of using this approach to determine the efficacy of therapeutic agents aimed at altering neutrophil migration to the lungs.
引用
- Tregay N, Begg M, Cahn A, et al. Use of autologous 99mTechnetium-labelled neutrophils to quantify lung neutrophil clearance in COPD. Thorax. 2019. PMID: 30674586. doi:10.1136/thoraxjnl-2018-212509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。